Alec Stranahan
Stock Analyst at Bank of America Securities
(3.96)
# 1,827
Out of 4,712 analysts
622
Total ratings
50.1%
Success rate
4.9%
Average return
Main Sectors:
Stocks Rated by Alec Stranahan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BEAM Beam Therapeutics | Reiterated: Buy | $43 | $25.18 | +70.80% | 25 | Sep 8, 2026 | |
| ERAS Erasca | Reiterated: Hold | $20 | $15.70 | +27.39% | 28 | Aug 26, 2026 | |
| RVMD Revolution Medicines | Reiterated: Buy | $225 | $207.68 | +8.34% | 37 | Aug 26, 2026 | |
| RGNX REGENXBIO | Reiterated: Buy | $15 | $8.73 | +71.82% | 29 | Aug 24, 2026 | |
| PRQR ProQR Therapeutics | Initiated Coverage: Buy | $8 | $1.99 | +302.01% | 1 | Aug 20, 2026 | |
| MRNA Moderna | Upgraded: Hold | $40 → $170 | $135.61 | +25.36% | 26 | Aug 19, 2026 | |
| IMTX Immatics | Reiterated: Buy | $17 | $9.11 | +86.61% | 18 | Aug 18, 2026 | |
| AKTS Aktis Oncology | Reiterated: Buy | $34 | $24.06 | +41.31% | 9 | Aug 14, 2026 | |
| CADL Candel Therapeutics | Reiterated: Hold | $9 → $12 | $12.17 | -1.40% | 18 | Aug 14, 2026 | |
| CATX Perspective Therapeutics | Reiterated: Hold | $6 → $5 | $2.99 | +67.22% | 18 | Aug 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $6 → $5 | $1.44 | +247.22% | 16 | Aug 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $19 | $13.26 | +43.29% | 17 | Aug 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7 → $6 | $3.17 | +89.27% | 13 | Aug 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $6 | $3.22 | +86.63% | 24 | Aug 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $17 | $4.81 | +253.43% | 7 | Aug 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $1 | $2.27 | -55.95% | 16 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $35 | $18.21 | +92.20% | 2 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $87 → $88 | $71.96 | +22.29% | 19 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | n/a | $2.77 | - | 10 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $21 → $22 | $19.33 | +13.81% | 22 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $19 → $17 | $12.21 | +39.23% | 19 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $8 → $7 | $9.85 | -28.93% | 42 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $16 → $15 | $10.81 | +38.76% | 21 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $17 → $20 | $24.94 | -19.81% | 19 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $83 → $82 | $53.45 | +53.41% | 27 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $20 → $21 | $54.65 | -61.57% | 38 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $396 → $392 | $348.09 | +12.61% | 32 | Aug 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $17 → $16 | $13.57 | +17.91% | 23 | Jul 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $46 | $34.63 | +32.83% | 34 | Jul 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Sell | $800 → $565 | $807.65 | n/a | 3 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $1,150 → $1,100 | $1,124.21 | n/a | 3 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $6 → $5 | $26.27 | n/a | 2 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $10 → $1 | $8.07 | n/a | 4 | Dec 2, 2022 |
Beam Therapeutics
Sep 8, 2026
Reiterated: Buy
Price Target: $43
Current: $25.18
Upside: +70.80%
Erasca
Aug 26, 2026
Reiterated: Hold
Price Target: $20
Current: $15.70
Upside: +27.39%
Revolution Medicines
Aug 26, 2026
Reiterated: Buy
Price Target: $225
Current: $207.68
Upside: +8.34%
REGENXBIO
Aug 24, 2026
Reiterated: Buy
Price Target: $15
Current: $8.73
Upside: +71.82%
ProQR Therapeutics
Aug 20, 2026
Initiated Coverage: Buy
Price Target: $8
Current: $1.99
Upside: +302.01%
Moderna
Aug 19, 2026
Upgraded: Hold
Price Target: $40 → $170
Current: $135.61
Upside: +25.36%
Immatics
Aug 18, 2026
Reiterated: Buy
Price Target: $17
Current: $9.11
Upside: +86.61%
Aktis Oncology
Aug 14, 2026
Reiterated: Buy
Price Target: $34
Current: $24.06
Upside: +41.31%
Candel Therapeutics
Aug 14, 2026
Reiterated: Hold
Price Target: $9 → $12
Current: $12.17
Upside: -1.40%
Perspective Therapeutics
Aug 14, 2026
Reiterated: Hold
Price Target: $6 → $5
Current: $2.99
Upside: +67.22%
Aug 14, 2026
Reiterated: Buy
Price Target: $6 → $5
Current: $1.44
Upside: +247.22%
Aug 14, 2026
Reiterated: Buy
Price Target: $19
Current: $13.26
Upside: +43.29%
Aug 14, 2026
Reiterated: Buy
Price Target: $7 → $6
Current: $3.17
Upside: +89.27%
Aug 12, 2026
Reiterated: Hold
Price Target: $6
Current: $3.22
Upside: +86.63%
Aug 12, 2026
Reiterated: Buy
Price Target: $17
Current: $4.81
Upside: +253.43%
Aug 7, 2026
Reiterated: Sell
Price Target: $1
Current: $2.27
Upside: -55.95%
Aug 7, 2026
Reiterated: Buy
Price Target: $35
Current: $18.21
Upside: +92.20%
Aug 7, 2026
Reiterated: Buy
Price Target: $87 → $88
Current: $71.96
Upside: +22.29%
Aug 7, 2026
Reiterated: Sell
Price Target: n/a
Current: $2.77
Upside: -
Aug 7, 2026
Reiterated: Buy
Price Target: $21 → $22
Current: $19.33
Upside: +13.81%
Aug 7, 2026
Reiterated: Hold
Price Target: $19 → $17
Current: $12.21
Upside: +39.23%
Aug 7, 2026
Reiterated: Sell
Price Target: $8 → $7
Current: $9.85
Upside: -28.93%
Aug 7, 2026
Reiterated: Buy
Price Target: $16 → $15
Current: $10.81
Upside: +38.76%
Aug 7, 2026
Reiterated: Hold
Price Target: $17 → $20
Current: $24.94
Upside: -19.81%
Aug 5, 2026
Reiterated: Buy
Price Target: $83 → $82
Current: $53.45
Upside: +53.41%
Aug 5, 2026
Reiterated: Sell
Price Target: $20 → $21
Current: $54.65
Upside: -61.57%
Aug 3, 2026
Reiterated: Buy
Price Target: $396 → $392
Current: $348.09
Upside: +12.61%
Jul 31, 2026
Reiterated: Buy
Price Target: $17 → $16
Current: $13.57
Upside: +17.91%
Jul 30, 2026
Reiterated: Buy
Price Target: $46
Current: $34.63
Upside: +32.83%
Dec 10, 2024
Initiated Coverage: Sell
Price Target: $800 → $565
Current: $807.65
Upside: n/a
Nov 1, 2024
Rated: Buy
Price Target: $1,150 → $1,100
Current: $1,124.21
Upside: n/a
Aug 15, 2023
Reiterated: Buy
Price Target: $6 → $5
Current: $26.27
Upside: n/a
Dec 2, 2022
Reiterated: Sell
Price Target: $10 → $1
Current: $8.07
Upside: n/a